Accumulation and cytotoxicity of amyloid beta (Aβ) are understood as the major cause of Alzheimer's disease (AD). There is evidence that naturally occurring antibodies against amyloid beta (Aβ) protein play a role in Aβ-clearance, and such a mechanism appears to be impaired in AD. In the present study, the anti-Aβ antibodies in the serum from individuals with and without late onset AD were measured using ELISA and dot-blot methods. Aβ auto-antibodies in serum were mainly targeted to Aβ1-15 epitope and its titer was significantly lower in AD patients than elderly non-AD controls (NC). The dot-blot analysis further demonstrated that auto-antibodies against fibrillar Aβ42, Aβ1-15 and Aβ16-30 epitopes were all in a lower level in AD than in NC. The isotypes of the auto-antibodies were mainly non-inflammatory IgG2 type. We also analyzed the relationship of auto-Aβ antibody levels with the genotypes of apolipoprotein E (ApoE) and ANKK1/DRD2 gene.
Introduction
Alzheimer disease (AD) is a progressive neurodegenerative disease associated with disruption of neuronal function in the hippocampus and cerebral cortex, which gradually deteriorates the cognition, function, and behavior of the patients (Schenk et al., 1999) . Increased accumulation and deposition of amyloid β (Aβ) protein in the form of plaques are thought to be the leading causes, and clearance of Aβ from the brain has been a major focus for the prevention and treatment of AD. Active immunization with Aβ peptide increased blood anti-Aβ antibodies and thus decreased brain Aβ plaque burden in AD mouse models (Schenk et al., 1999; Morgan et al., 2000) as well as in AD patients (Gilman et al., 2005; Holmes et al., 2008) . Administration of N-terminal Aβ antibodies was also effective in reducing plaques in AD mouse models and in AD patients (DeMattos et al., 2001; Mangialasche et al., 2010) . These data indicate that pre-existing autoantibodies against Aβ in the blood may play an important role in the plaque formation and such an immune mechanism may have been impaired in AD.
Many studies have been conducted to compare serum levels of Aβ auto-antibodies in AD and in age-matched non-AD control (NC) subjects. The results of these studies have been inconsistent: some reported that Aβ auto-antibodies in AD were lower than in normal subjects (Klatka et al., 1996; Jellinger, 2009) , structural conformation of Aβ1-42, and/or small sample size. Despite the relatively large number of studies being conducted, the epitope-specific binding and isotyping of the auto-antibodies against Aβ1-42 have not been reported. The present study therefore has sought to measure epitope-specific autoantibodies against Aβ1-42 peptide in AD patients by comparison with the normal age-matched control subjects (NC). Our results indicate that naturally occurred Aβ antibodies mainly target Aβ1-15 epitope in both AD and NC subjects, as evidenced by the measurements of various Aβ epitopes with ELISA method, and in addition, its levels are significantly reduced in AD, especially in patients over 65 years of age, in comparison with those of NC subjects. Dot-blot analysis further Journal of Neuroimmunology 274 (2014) [168] [169] [170] [171] [172] [173] 
